---
anonymous_label: OUT-16
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 60a2366174d35bb731889d9ed8dd7c1bc2d509c166deec8b96e1334dec6f7568
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-16

I recommend that you commit to the **Claim File Review**.

### Reasoning and Trade-offs
Your current situation is a "false positive" trap. The executive team sees rising expansion bookings and usage percentages, but the underlying data suggests these are lagging indicators driven by sales incentives (bundle pricing) and administrative behavior (ops managers running samples), rather than core product-market fit for the end-user.

The most dangerous signal is the "abandonment" in the health-liability segment and the adjusters falling back to manual notes. In B2B workflow software, **usage $\neq$ value**. High usage by managers for enablement meetings is "performance art"; it doesn't prove the tool solves a pain point for the person actually doing the work.

Here is why the other options are insufficient:
*   **Scaling Broadly:** This is premature. You have evidence of "silent churn" (the regional carriers) and a lack of explainability in regulated segments. Scaling now would likely accelerate churn once the bundle-pricing honeymoon ends.
*   **Usage Quality Sprint:** This measures *behavior*, not *utility*. You already know the return rate is low for adjusters; knowing exactly how low it is via a dashboard doesn't tell you *why* they are abandoning the tool or how to fix it.
*   **Commercial Cleanroom:** This tests *willingness to pay*, but you have a product utility problem, not a pricing problem. If the adjusters aren't using it because they can't explain the output to reviewers, no amount of pricing strategy will save the renewal.
*   **Narrowing to Health-Liability:** This is a premature pivot. You know it's failing there, but you don't yet know if it's failing everywhere or just in highly regulated environments.

The **Claim File Review** is the only option that provides "ground truth." By auditing the actual claim files, you move from *proxy metrics* (clicks/bookings) to *outcome metrics* (accepted vs. overridden suggestions). This will tell you if DraftPath is actually providing a correct "next action" or if it is simply generating noise that adjusters are too tired to correct in a support ticket.

### The strongest reason against this recommendation
The Claim File Review is slow, manual, and "unsexy" compared to the growth narrative currently fueling the executive team's confidence. By choosing this, you are effectively telling the CEO and the Board that the "surprisingly strong quarter" may be an illusion. You risk appearing as a bottleneck to growth or "too academic" at a moment when the company feels it has found its stride. You are sacrificing the momentum of a "win" to investigate a potential failure.

### Observable evidence that would change my mind
I would pivot from the Claim File Review to **Scaling Broadly** if you can produce evidence that the "manual notes" fallback is actually a result of **UI friction** (e.g., it takes too many clicks to accept a plan) rather than **trust/utility friction** (e.g., the plan is wrong or unexplainable).

If a quick audit of the "enablement" meetings reveals that adjusters are actually saying, *"I love this, I just don't know how to move the data into my final report,"* then you have a distribution problem, not a value problem. In that specific case, the risk of scaling is lower because the core utility is already proven. However, based on the current reports of "impossible to explain" actions in regulated segments, this is unlikely.
